Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease


Autoria(s): BUSTAMANTE, Jacinta; ARIAS, Andres A.; VOGT, Guillaume; PICARD, Capucine; GALICIA, Lizbeth Blancas; PRANDO, Carolina; GRANT, Audrey V.; MARCHAL, Christophe C.; HUBEAU, Marjorie; CHAPGIER, Ariane; BEAUCOUDREY, Ludovic de; PUEL, Anne; FEINBERG, Jacqueline; VALINETZ, Ethan; JANNIERE, Lucile; BESSE, Celine; BOLAND, Anne; BRISSEAU, Jean-Marie; BLANCHE, Stephane; LORTHOLARY, Olivier; FIESCHI, Claire; EMILE, Jean-Francois; BOISSON-DUPUIS, Stephanie; AL-MUHSEN, Saleh; WODA, Bruce; NEWBURGER, Peter E.; CONDINO-NETO, Antonio; DINAUER, Mary C.; ABEL, Laurent; CASANOVA, Jean-Laurent
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

20/10/2012

20/10/2012

2011

Resumo

Germline mutations in CYBB, the human gene encoding the gp91(phox) subunit of the phagocyte NADPH oxidase, impair the respiratory burst of all types of phagocytes and result in X-linked chronic granulomatous disease (CGD). We report here two kindreds in which otherwise healthy male adults developed X-linked recessive Mendelian susceptibility to mycobacterial disease (MSMD) syndromes. These patients had previously unknown mutations in CYBB that resulted in an impaired respiratory burst in monocyte-derived macrophages but not in monocytes or granulocytes. The macrophage-specific functional consequences of the germline mutation resulted from cell-specific impairment in the assembly of the NADPH oxidase. This `experiment of nature` indicates that CYBB is associated with MSMD and demonstrates that the respiratory burst in human macrophages is a crucial mechanism for protective immunity to tuberculous mycobacteria.

Institut National de la Sante et de la Recherche Medicale

Institut National de la Santé et de la Recherche Médicale (Inserm)

European Union[NEOTIM EEA05095KKA]

European Union

European Union[HEALTH-F3-2008-200732]

European Union

March of Dimes

March of Dimes[RO5050KK]

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

FAPESP Fundacao de Amparo a Pesquisa do Estado de Sao Paulo

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

CNPq Conselho Nacional de Desenvolvimento Cientifico e Tecnologico

Fondation BNP-Paribas

Fondation BNP-Paribas

Fondation Schlumberger

Fondation Schlumberger

Institut Universitaire de France

Institut Universitaire de France

Agence Nationale de Recherche

Agence Nationale de la Recherche de la France (ANR)

Rockefeller University Center for Clinical and Translational Science[5UL1RR024143-03]

Rockefeller University Center for Clinical and Translational Science

Rockefeller University

Rockefeller University

National Institutes of Health (NIH)[AI 079788]

U.S. National Institutes of Health (NIH)

National Institutes of Health (NIH)[DK54369]

U.S. National Institutes of Health (NIH)

National Institutes of Health (NIH)[HL045635]

U.S. National Institutes of Health (NIH)

Riley Children`s Foundation

Riley Children`s Foundation

Howard Hughes Medical Institute

Howard Hughes Medical Institute

Identificador

NATURE IMMUNOLOGY, v.12, n.3, p.213-U47, 2011

1529-2908

http://producao.usp.br/handle/BDPI/28248

10.1038/ni.1992

http://dx.doi.org/10.1038/ni.1992

Idioma(s)

eng

Publicador

NATURE PUBLISHING GROUP

Relação

Nature Immunology

Direitos

restrictedAccess

Copyright NATURE PUBLISHING GROUP

Palavras-Chave #CHRONIC GRANULOMATOUS-DISEASE #PHAGOCYTE RESPIRATORY BURST #HIGH-LEVEL RECONSTITUTION #NADPH OXIDASE ACTIVITY #FLAVOCYTOCHROME B(558) #CYTOCHROME B(558) #INTERFERON-GAMMA #REACTIVE OXYGEN #PRIMARY IMMUNODEFICIENCIES #CLINICAL-FEATURES #Immunology
Tipo

article

original article

publishedVersion